Clozapine vs Olanzapine (Zyprexa)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Clozapine
Marketed by HLS Therapeutics Inc.
NCT00250575 · Phase 3 · completed
The study was open-label, single-arm, and had no placebo or active comparator; all 43 participants received clozapine. Its primary measures focused on hematological tests, blood-related adverse events, and monitoring-system compliance rather than a clinical symptom endpoint, and no results are posted.
Next expected readout: April 2027 · NCT04580134 (registry estimate)
Reported efficacy
Treatment efficacy rate (baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months); All-cause dropout rate (baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months): Primary 1, symptomatic response (40% or more PANSS total reduction) in phase 2 among 111 re-randomized nonresponders: clozapine 62.5% (20/32) vs amisulpride 44.7% (17/38) vs olanzapine 31.7% (13/41) (chi-square 6.9; P=.03), met. Primary 2, time to all-cause discontinuation: the paper reports no clear difference between treatment groups, missed. (mixed)
Result source: NCT03510325
Olanzapine (Zyprexa)
Marketed by Cheplapharm Arzneimittel GmbH and partners
NCT03510325 · Phase 3 · completed
This trial randomly assigned 762 people with schizophrenia to active antipsychotic treatments, with outcomes rated by masked assessors but treatment assignment itself not blinded. Among 111 participants who had not responded to first-line treatment and were reassigned to a second drug, 31.7% responded on olanzapine against 44.7% on amisulpride and 62.5% on clozapine, a significant difference across the three (p=0.03). Olanzapine was the least effective of the second-line options tested.
Next expected readout: February 2027 · NCT03781115 (registry estimate)
Reported efficacy
Treatment efficacy rate (baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months); All-cause dropout rate (baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months): Phase 2 symptomatic response (≥40% PANSS reduction) among 111 first-episode-treatment nonresponders re-randomized to second-line therapy: olanzapine 31.7% (13/41) vs amisulpride 44.7% (17/38) vs clozapine 62.5% (20/32); chi-square=6.9, P=.03 (missed)
Result source: NCT03510325
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.
| Key endpoint | Clozapine | Olanzapine (Zyprexa) |
|---|---|---|
| PANSS total, change | —Not posted · NCT00649844 | -8.8 vs 4.5−13.3 vs placeboNCT00686998 |
| CGI-S, change | —Not posted · NCT00649844 | —Not posted · NCT00083668 |
| PANSS response | —Not posted · NCT00649844 | 31.7% vs 44.7%avs amisulprideNCT03510325 |
| PSP, change | —Not posted · NCT00649844 | —Not posted · NCT00083668 |
| Relapse (% of patients) | —Not posted · NCT00649844 | —Not posted · NCT00083668 |
PANSS total, change
- Clozapine
- —Not posted · NCT00649844
- Olanzapine (Zyprexa)
- -8.8 vs 4.5−13.3 vs placeboNCT00686998
CGI-S, change
- Clozapine
- —Not posted · NCT00649844
- Olanzapine (Zyprexa)
- —Not posted · NCT00083668
PANSS response
- Clozapine
- —Not posted · NCT00649844
- Olanzapine (Zyprexa)
- 31.7% vs 44.7%avs amisulprideNCT03510325
PSP, change
- Clozapine
- —Not posted · NCT00649844
- Olanzapine (Zyprexa)
- —Not posted · NCT00083668
Relapse (% of patients)
- Clozapine
- —Not posted · NCT00649844
- Olanzapine (Zyprexa)
- —Not posted · NCT00083668
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Clozapine: 3 of 4 rows · Olanzapine (Zyprexa): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Clozapine | Olanzapine (Zyprexa) |
|---|---|---|
| Dropout rate | 41.7%a NCT01639872 · Phase 4 · registry result, not featured evidence show 2 more results0% NCT00498550 · Phase 4 · registry result, not featured evidence 17.2% NCT02404155 · Phase na · registry result, not featured evidence | 63.4%Olanzapine/Intense Behavioral Weiga NCT00982020 · Phase 4 · registry result, not featured evidence · combination show 14 more results55.9%Olanzapine/Standard Behavioral Wei NCT00982020 · Phase 4 · registry result, not featured evidence · combination 38.2% NCT00190749 · Phase 4 · registry result, not featured evidence 60.3% NCT00088465 · Phase 3 · registry result, not featured evidence 0% NCT00797277 · Phase 3 · registry result, not featured evidence 22%Olanzapine NCT00401973 · Phase 3 · registry result, not featured evidence 34.2%Olanzapine + Amantadine NCT00401973 · Phase 3 · registry result, not featured evidence · combination 31.5%Olanzapine + Metformin NCT00401973 · Phase 3 · registry result, not featured evidence · combination 18.2% NCT00686998 · Phase 2 · registry result, not featured evidence —Cohort 1: Olanzapine (Fast-D) NCT06319170 · Phase 1 · registry result, not featured evidence —Cohort 2: Olanzapine (To-be-market NCT06319170 · Phase 1 · registry result, not featured evidence —Cohort 3: Olanzapine (Slow-C) NCT06319170 · Phase 1 · registry result, not featured evidence —3 mg NCT00512070 · Phase na · registry result, not featured evidence · combination —0.3 mg NCT00512070 · Phase na · registry result, not featured evidence · combination —Olanzapine Only NCT00512070 · Phase na · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT01639872 · Phase 4 · registry result, not featured evidence show 2 more results— NCT00498550 · Phase 4 · registry result, not featured evidence — NCT02404155 · Phase na · registry result, not featured evidence | 14.9%Olanzapine/Intense Behavioral Weiga NCT00982020 · Phase 4 · registry result, not featured evidence · combination show 14 more results18.6%Olanzapine/Standard Behavioral Wei NCT00982020 · Phase 4 · registry result, not featured evidence · combination 0% NCT00190749 · Phase 4 · registry result, not featured evidence 8.3% NCT00088465 · Phase 3 · registry result, not featured evidence — NCT00797277 · Phase 3 · registry result, not featured evidence 4%Olanzapine NCT00401973 · Phase 3 · registry result, not featured evidence 10.5%Olanzapine + Amantadine NCT00401973 · Phase 3 · registry result, not featured evidence · combination 5.5%Olanzapine + Metformin NCT00401973 · Phase 3 · registry result, not featured evidence · combination 4.5% NCT00686998 · Phase 2 · registry result, not featured evidence —Cohort 1: Olanzapine (Fast-D) NCT06319170 · Phase 1 · registry result, not featured evidence —Cohort 2: Olanzapine (To-be-market NCT06319170 · Phase 1 · registry result, not featured evidence —Cohort 3: Olanzapine (Slow-C) NCT06319170 · Phase 1 · registry result, not featured evidence —3 mg NCT00512070 · Phase na · registry result, not featured evidence · combination —0.3 mg NCT00512070 · Phase na · registry result, not featured evidence · combination —Olanzapine Only NCT00512070 · Phase na · registry result, not featured evidence |
| Serious AEs | 13%a NCT01639872 · Phase 4 · registry result, not featured evidence show 2 more results26.7% NCT00498550 · Phase 4 · registry result, not featured evidence 6.9% NCT02404155 · Phase na · registry result, not featured evidence | 19.8%Olanzapine/Intense Behavioral Weiga NCT00982020 · Phase 4 · registry result, not featured evidence · combination show 14 more results12.7%Olanzapine/Standard Behavioral Wei NCT00982020 · Phase 4 · registry result, not featured evidence · combination 2.9% NCT00190749 · Phase 4 · registry result, not featured evidence 18.3% NCT00088465 · Phase 3 · registry result, not featured evidence 0% NCT00797277 · Phase 3 · registry result, not featured evidence —Olanzapine NCT00401973 · Phase 3 · registry result, not featured evidence —Olanzapine + Amantadine NCT00401973 · Phase 3 · registry result, not featured evidence · combination —Olanzapine + Metformin NCT00401973 · Phase 3 · registry result, not featured evidence · combination 0% NCT00686998 · Phase 2 · registry result, not featured evidence 0%Cohort 1: Olanzapine (Fast-D) NCT06319170 · Phase 1 · registry result, not featured evidence 3.2%Cohort 2: Olanzapine (To-be-market NCT06319170 · Phase 1 · registry result, not featured evidence 0%Cohort 3: Olanzapine (Slow-C) NCT06319170 · Phase 1 · registry result, not featured evidence 0%3 mg NCT00512070 · Phase na · registry result, not featured evidence · combination 25%0.3 mg NCT00512070 · Phase na · registry result, not featured evidence · combination 5.9%Olanzapine Only NCT00512070 · Phase na · registry result, not featured evidence |
| Most frequent reported AEs | a other-sialorrhea 43.5% weight gain 30.4% sedation 21.7% NCT01639872 · Phase 4 · registry result, not featured evidence show 2 more resultsgastrointestinal disorder - other: hypersalivation 66.7% somnolence 60% weight gain 40% NCT00498550 · Phase 4 · registry result, not featured evidence salivation 68.2% sedation 52.9% malaise 52.6% NCT02404155 · Phase na · registry result, not featured evidence | a somnolence 23.8% weight increased 20.8% headache 19.8% NCT00982020 · Phase 4 · registry result, not featured evidence · combination show 14 more resultsweight increased 30.4% headache 18.6% somnolence 18.6% NCT00982020 · Phase 4 · registry result, not featured evidence · combination weight increased 16.2% headache 10.3% sedation 10.3% NCT00190749 · Phase 4 · registry result, not featured evidence weight increased 14.4% anxiety 9.7% insomnia 9.7% NCT00088465 · Phase 3 · registry result, not featured evidence insomnia 10% somnolence 8% increased appetite 6% NCT00401973 · Phase 3 · registry result, not featured evidence somnolence 6.6% dry mouth 5.3% insomnia 5.3% NCT00401973 · Phase 3 · registry result, not featured evidence · combination diarrhoea 13.7% somnolence 11% nausea 6.8% NCT00401973 · Phase 3 · registry result, not featured evidence · combination weight increased 40.9% (placebo 0%) increased appetite 18.2% (placebo 2.4%) somnolence 18.2% (placebo 2.4%) NCT00686998 · Phase 2 · registry result, not featured evidence injection site irritation 6.9% injection site pain 6.9% psychotic disorder 6.9% NCT06319170 · Phase 1 · registry result, not featured evidence injection site pain 9.7% somnolence 9.7% blood creatine phosphokinase increased 6.5% NCT06319170 · Phase 1 · registry result, not featured evidence alanine aminotransferase increased 6.5% aspartate aminotransferase increased 6.5% somnolence 6.5% NCT06319170 · Phase 1 · registry result, not featured evidence 3 mg abnormal lab values 33.3% decreased appetite 16.7% depression 16.7% NCT00512070 · Phase na · registry result, not featured evidence · combination 0.3 mg abnormal lab values 50% depression 25% psychotic symptoms 25% NCT00512070 · Phase na · registry result, not featured evidence · combination abnormal lab values 29.4% insomnia/sleep disturbance 23.5% diarrhea 17.6% NCT00512070 · Phase na · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Clozapine
Olanzapine (Zyprexa)
show 3 more results
show 1 more result
show 1 more result
show 2 more results
show 1 more result
+ 16 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Clozapine's landscape · Olanzapine (Zyprexa)'s landscape